Wockhardt Ltd - Company Profile
Powered by 
All the sales intelligence you need on Wockhardt Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Wockhardt Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Wockhardt Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Wockhardt Ltd (Wockhardt) is a pharmaceutical and biotechnology company that focuses on antibiotics research and development. The company discovers, develops, and commercializes antibiotics aimed at combating multi-drug resistant bacterial pathogens. Its products are designed for use in treating serious infections, primarily in intensive care settings, and are applicable across healthcare industries. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, and novel drug delivery systems (NDDS). Wockhardt operates through a network of distribution channels, serving markets in the US, UK, Ireland, Switzerland, Mexico, Russia, and other countries. The company has research facilities in India and the UK, and a manufacturing facility in Ireland, with a significant presence in Europe and India. Wockhardt is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai, Maharashtra, 400051
Website
www.wockhardt.com
Telephone
91 22 26534444
No of Employees
2,296
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
WOCKPHARMA (NSE)
Revenue (2024)
$360.0M
7.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
89.8%
(2024 vs 2023)
Market Cap*
$2.4B
Net Profit Margin (2024)
XYZ
90.6%
(2024 vs 2023)
* As of and is in US$
Wockhardt Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Active Pharmaceutical Ingredients | Biovac-B |
| Vaccines | Wepox |
| New Chemical Entities Pipeline: | Wosulin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In May, the company entered into an agreement to sell its USFDA-approved Abbreviated New Drug Application for Topiramate HCl 25, 50, 100, and 200 mg tablets to Senores Pharmaceuticals, Inc., USA. |
| 2025 | Regulatory Approval | In January, the company received approval from the Central Drugs Standard Control Organization (CDSCO) for Miqnaf(nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in adults. |
| 2023 | Business / Operations Closure | In February, the company shut down its manufacturing facility at Morton Grove, Illinois, the US. |
Competitor Comparison
| Key Parameters | Wockhardt Ltd | Alcon Inc | Sandoz Inc | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | Switzerland | United States of America | India | India |
| City | Mumbai | Fribourg | Princeton | Mumbai | Hyderabad |
| State/Province | Maharashtra | Freiburg | New Jersey | Maharashtra | Telangana |
| No. of Employees | 2,296 | 25,942 | - | 43,000 | 26,944 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Habil Khorakiwala | Chairman | Executive Board | - | - |
| Deepak Madnani | Chief Financial Officer | Senior Management | 2022 | - |
| Avijit Deb | Chief Digital Officer- Information Technology | Senior Management | - | - |
| Murtaza Khorakiwala | Managing Director | Executive Board | 2009 | - |
| Huzaifa Khorakiwala | Director | Executive Board | 1996 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer